Search results

1. Merck’s latest move is in bispecifics

   … The latest update from a phase 1 study of the project, at ASH 2023, found a 63% response rate in relapsed/refractory …

   
    

   Madeleine Armstrong
    
   - 06/19/2024 - 16:48

2. A new order in BTK inhibition

   … one responder had a C481S BTK mutation Source: ASH 2023. Conferences Trial …

   
    

   Jacob Plieth
    
   - 01/02/2024 - 15:04

3. ASH 2023 – Sympatico gives Imbruvica a second chance

   ASH 2023 – Sympatico gives Imbruvica a second chance …

   
    

   Jacob Plieth
    
   - 12/15/2023 - 13:39

4. ASH 2023 movers – an unexpected comeback for MorphoSys

   ASH 2023 movers – an unexpected comeback for MorphoSys …

   
    

   Jacob Plieth
    
   - 12/18/2023 - 14:37

5. ASH 2023 – Genmab's son of Darzalex in focus

   ASH 2023 – Genmab's son of Darzalex in focus … development of GEN3014 .   GEN3014 safety data at ASH 2023 Source: Dr Sebastian Grosicki & ASH. …

   
    

   Madeleine Armstrong
    
   - 12/15/2023 - 13:39

6. ASH 2023 – Arcellx still hopes to challenge Carvykti

   ASH 2023 – Arcellx still hopes to challenge Carvykti …

   
    

   Madeleine Armstrong
    
   - 12/14/2023 - 17:01

7. ASH 2023 – the markets forgive MorphoSys

   ASH 2023 – the markets forgive MorphoSys …

   
    

   Jacob Plieth
    
   - 04/26/2024 - 15:06

8. ASH 2023 – Regeneron defends its bispecifics

   ASH 2023 – Regeneron defends its bispecifics …

   
    

   Madeleine Armstrong
    
   - 12/12/2023 - 05:08

9. ASH 2023 – a short-lived success for Poseida

   ASH 2023 – a short-lived success for Poseida …

   
    

   Jacob Plieth
    
   - 12/12/2023 - 01:08

10. ASH 2023 – Incyte hopes to add axatilimab to the arsenal

    ASH 2023 – Incyte hopes to add axatilimab to the arsenal … Axatilimab Anti-CSF-1R Mab Syndax/ Incyte ASH 2023: 74% ORR at lowest dose in ≥3L chronic GvHD in …

    
     

    Madeleine Armstrong
     
    - 12/12/2023 - 01:09